Modified HGP-30 heteroconjugates, compositions and methods of use
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 15, 2000
Grant Date -
N/A
app pub date -
Aug 9, 1996
filing date -
Aug 9, 1996
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A heteroconjugate is formed by linking a T cell binding ligand (TCBL) such as Peptide J of .beta.-2 microglobulin to a modified HGP-30 antigentic peptide fragment of p17 gag peptide, such as. for example ATL YSV HQR IDV KDT KEA LEK IEE EQN KS (SEQ ID NO: 5) The heteroconjugate is effective in eliciting a THI directed immune response and provides a vaccine composition for treating or preventing AIDS.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully